Phase 2 RCT in adults with FSGS (67 randomised, 60 analysed): proteinuria response at 12 weeks was 35% across BI 764198 doses vs 7% with placebo (OR 4.9); 44%, 14% and 43% at 20, 40 and 80 mg; adverse events similar (71% in each).
RCTn = 67
Trachtman et al. TRPC6 inhibition for the treatment of focal segmental glomerulosclerosis: a randomised, placebo-controlled, phase 2 trial of BI 764198